drugset / Trial / NCT01214486

Measurement of Plasma and Intracellular Concentrations of Raltegravir

NCT01214486

Completed 12 enrolled University of Nebraska
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to analyze and compare plasma and intracellular concentrations of Raltegravir (RAL) in blood plasma and in peripheral blood mononuclear cells, using high performance liquid chromatography (HPLC).

Timeline

Start
2010-10-01
Primary completion
2011-04-30
Completion
2011-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Raltegravir Other / unclassified 400 mg
Subject Raltegravir Other / unclassified 800 mg